References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2015-3-76-82

vtio-569

Research Article

Обзор литературы

Literature Reviews

ТРАНСФОРМИРУЮЩИЙ ФАКТОР РОСТА 1 ПРИ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ

TRANSFORMING GROWTH FACTOR 1 AT LIVER TRANSPLANTATION

Курабекова

Р. М.

Kurabekova

R. M.

Шевченко

О. П.

Shevchenko

O. P.

123182, г. Москва, ул. Щукинская, д. 1. Тел. (499) 190-38-77

1, Schukinskaya Str., Moscow, 123182, Russian Federation. Теl. (499) 190-38-77

transplant2009@mail.ru

Цирульникова

О. М.

Tsiroulnikova

O. M.

ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская ФедерацияРоссияV.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian FederationRussian Federation

ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация Кафедра трансплантологии и искусственных органов ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», Москва, Российская ФедерацияРоссияV.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University, Department of transplantology and artifi cial organs, Moscow, Russian FederationRussian Federation

2015

09102015

1737682

2015

Курабекова Р.М., Шевченко О.П., Цирульникова О.М.

Kurabekova R.M., Shevchenko O.P., Tsiroulnikova O.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/569

Обзор литературы посвящен анализу роли трансформирующего фактор роста бета 1 (TGF-β1) при трансплантации печени. TGF-β1 играет ключевую роль в развитии фиброза печени, а также в развитии иммунного ответа; его концентрация в ткани и в крови изменяется при заболеваниях печени. Уровень TGF-β1 в крови реципиентов печени связан с развитием фиброза, формированием иммунной толерантности и иммунным ответом на активную инфекцию. Измерение уровня TGF-β1 при трансплантации печени может иметь диагностическое и прогностическое значение при оценке состояния трансплантата. В настоящее время клинических данных о роли цитокина при трансплантации печени накоплено недостаточно, и необходимы дальнейшие исследования связи уровня TGF-β1 с различными клиническими и лабораторными показателями у реципиентов печени. В обзоре проанализированы 54 источника литературы, более половины из которых опубликованы в последние пять лет.

This review summarizes the current literature devoted to the analysis of the role of transforming growth factor beta 1 (TGF-β1) at liver transplantation. TGF-β1 plays a key role in the development of liver fi brosis, as well as in development of the immune response; its concentration in the blood and tissue changes in liver diseases. TGF-β1 levels in the blood of the recipients are associated with the development of liver fi brosis, the formation of immune tolerance and immune response to active infection. Measuring the level of TGF-β1 at liver transplantation may have diagnostic and prognostic value for assessing the graft condition. Currently, clinical data on the role of the cytokine at liver transplantation are not accumulated enough and further research on the relation of TGF-β1 levels with different clinical and laboratory parameters in liver transplant patients is needed. The review analyzed 54 sources of literature, more than half of which were published in the last fi ve years.

трансплантация печениTGF-βбиомаркерыцитокины

liver transplantationTGF-β1biomarkerscytokines

References1

Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342 (18): 1350–1358.

Wynn TA. Cell ular and molecular mechanisms of fi brosis. J Pathol. 2008; 214 (2): 199–210.

Lee SJ, Kim KH , Park KK. Mechanisms of fi brogenesis in liver cirrhosis: The molecular aspects of epithelialmesenchymal transition. World J Hepatol. 2014; 6 (4): 207–216.

Valva P, Cascia to P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC et al. The role of serum biomarkers in predicting fi brosis progression in pediatric and adult hepatitis C virus chronic infection. PloS one. 2011; 6 (8): 17.

Harris WT, Muhl ebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL. Plasma TGF-beta(1) in pediatric cystic fi brosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol. 2011; 46 (7):688–695.

Vinagre I, Sanch ez-Quesada JL, Sanchez-Hernandez J, Santos D, Ordonez-Llanos J, De Leiva A et al. Infl ammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol. 2014; 13 (34): 1475–2840.

Lazarenko LM, Nik itina OE, Nikitin EV, Demchenko OM, Kovtonyuk GV, Ganova LO et al. Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions. Epma J. 2014; 5 (1):1878–5085.

Gruppuso PA, Mead JE, Fausto N. Transforming growth factor receptors in liver regeneration following partial hepatectomy in the rat. Cancer Res. 1990; 50 (5): 1464– 1469.

Kang LI, Mars WM, M ichalopoulos GK. Signals and cells involved in regulating liver regeneration. Cells. 2012; 1 (4): 1261–1292.

Massague J, Gomis R R. The logic of TGFbeta signaling. FEBS Lett. 2006; 580 (12): 2811–2820.

Yasmin Anum MY, Looi ML, Nor Aini AH, Merican I, Wahidah A, Mohd Radzi AH et al. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specifi city in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. Med J Malaysia. 2009; 64 (3): 223–227.

Okamoto Y, Gotoh Y, U emura O, Tanaka S, Ando T, Nishida M. Age-dependent decrease in serum transforming growth factor (TGF)-beta 1 in healthy Japanese individuals; population study of serum TGF-beta 1 level in Japanese. Dis Markers. 2005; 21 (2): 71–74.

Rosensweig JN, Omori M , Page K, Potter CJ, Perlman EJ, Thorgeirsson SS et al. Transforming growth factor-beta1 in plasma and liver of children with liver disease. Pediatr Res. 1998; 44 (3): 402–409.

Redondo S, Navarro-Dora do J, Ramajo M, Medina U, Molina-Sanchez P, Garces Z et al. Age-dependent defective GF-beta1 signaling in patients undergoing coronary artery bypass grafting. J Cardiothorac Surg. 2014; 9 (1): 1749–8090.

Kanzler S, Baumann M, Sc hirmacher P, Dries V, Bayer E, Gerken G et al. Prediction of progressive liver fi brosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat. 2001; 8 (6): 430–437.

Tsau YK, Lu MY, Ni YH. Ne phromegaly and elevated plasma hepatocyte growth factor-transforming growth factor-beta1 ratio in infants with fulminant hepatitis or biliary atresia. Am J Kidney Dis. 2001; 38 (2): 279–285.

Cheng CH, Tsau YK, Tsai IJ . Kidney volume and plasma hepatocyte growth factor-transforming growth factor beta1 ratio among children with biliary atresia before and after liver transplantation: the reversibility of nephromegaly. Am J Kidney Dis. 2005; 46 (5): 830–836.

Lebensztejn DM, Sobaniec-Lo towska M, Kaczmarski M, Werpachowska I, Sienkiewicz J. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fi brosis in children with chronic hepatitis B. Hepatogastroenterology. 2004; 51 (55): 229–233.

Hussein MH, Hashimoto T, Abd El-Hamid Daoud G, Kato T, Hibi M, Tomishige H et al. Pediatric patients receiving AB0-incompatible living related liver transplantation exhibit higher serum transforming growth factor-beta1, interferon-gamma and interleukin-2 levels. Pediatr Surg Int. 2011; 27 (3): 263–268.

Hussein MH, Hashimoto T, Suzu ki T, Daoud GA, Goto T, Nakajima Y et al. Children undergoing liver transplantation for treatment of inherited metabolic diseases are prone to higher oxidative stress, complement activity and transforming growth factor-beta1. Ann Transplant. 2013; 18: 63–68.

Briem-Richter A, Leuschner A, Krieger T, Grabhorn E, Fischer L, Nashan B et al. Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation. Pediatr Transplant. 2013; 17 (8): 757–764.

Fernandez-Yunquera A, Ripoll C, Banares R, Puerto M, Rincon D, Yepes I et al. Everolimus immunosuppression reduces the serum expression of fi brosis markers in liver transplant recipients. World J Transplant. 2014; 4 (2): 133–140.

Zhang Y, Wang YL, Liu YW, Li Q, Yuan YH, Niu WY et al. Change of peripheral blood mononuclear cells IFNgamma, IL-10, and TGF-beta1 mRNA expression levels with active human cytomegalovirus infection in orthotopic liver transplantation. Transplant Proc. 2009; 41 (5): 1767–1769.

Dudek K, Koziak K, Placha G, Korn asiewicz O, Zieniewicz K, Zurakowski J et al. Early expression of hepatocyte growth factor, interleukin-6, and transforming growth factor-beta1 and -beta2 in symptomatic infection in patients who have undergone liver transplantation. Transplant Proc. 2009; 41 (1): 240–245.

Kurabekova RM, Shevchenko OP, Tsir oulnikova OM, Tsiroulnikova IE, Olefi renko GA, Gautier SV. Transforming growth factor β 1 in children of early age with liver transplantation. Vestnik transplantologii i iskusstvennykh organov. 2014; XVI (4): 27–32. [In Russ]

Bissell DM, Wang SS, Jarnagin WR, R oll FJ. Cell-specifi c expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest. 1995; 96 (1): 447–455.

Ikeda H, Nagoshi S, Ohno A, Yanase M , Maekawa H, Fujiwara K. Activated rat stellate cells express c-met and respond to hepatocyte growth factor to enhance transforming growth factor beta1 expression and DNA synthesis. Biochem Biophys Res Commun. 1998; 250 (3):769–775.

Leask A, Abraham DJ. TGF-beta signali ng and the fi brotic response. FASEB J. 2004; 18 (7): 816–827.

Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C et al. IL-17A plays a critical role in the pathogenesis of liver fi brosis through hepatic stellate cell activation. J Immunol. 2013; 191 (4): 1835–1844.

Chari RS, Price DT, Sue SR, Meyers WC, Jirtle RL. Down-regulation of transforming growth factor beta receptor type I, II, and III during liver regeneration. Am J Surg. 1995; 169 (1): 126–131.

McMahon JB, Richards WL, del Campo AA, S ong MK, Thorgeirsson SS. Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat iver epithelial cells in culture. Cancer Res. 1986; 46 (9): 4665–4671.

Houck KA, Cruise JL, Michalopoulos G. Nor epinephrine modulates the growth-inhibitory effect of transforming growth factor-beta in primary rat hepatocyte cultures. J Cell Physiol. 1988; 135 (3): 551–555.

Russell WE, Coffey RJ, Jr., Ouellette AJ, Moses HL. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A. 1988; 85 (14): 5126–5130.

Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007; 26 (5): 579–591.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441 (7090): 235–238.

Marie JC, Liggitt D, Rudensky AY. Cellular me chanisms of fatal early-onset autoimmunity in mice with the T cell-specifi c targeting of transforming growth factor-beta receptor. Immunity. 2006; 25 (3): 441–454.

Li MO, Wan YY, Sanjabi S, Robertson AK, Flavel l RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24: 99–146.

Li W, Kuhr CS, Zheng XX, Carper K, Thomson AW, Reyes JD et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant. 2008; 8 (8): 1639–1651.

Nakano T, Lai CY, Goto S, Hsu LW, Kawamoto S, On o K et al. Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance. PloS one. 2012; 7 (5): 15.

Chen L, Zheng L, He W, Qiu M, Gao L, Liu J et al . Cotransfection with IL-10 and TGF-beta1 into immature dendritic cells enhances immune tolerance in a rat liver transplantation model. Am J Physiol Gastrointest Liver Physiol. 2014; 306 (7): 6.

Cheong HI, Lee JH, Hahn H, Park HW, Ha IS, Choi Y. Circulating VEGF and TGF-beta1 in children with idio pathic nephrotic syndrome. J Nephrol. 2001; 14 (4): 263–269.

Charles R, Chou HS, Wang L, Fung JJ, Lu L, Qian S . Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation. 2013; 96 (1): 17–24.

Jiang Z, Chen Y, Feng X, Jiang J, Chen T, Xie H et al. Hepatic stellate cells promote immunotolerance following orthotopic liver transplantation in rats via induction of T cell apoptosis and regulation of Th2/Th3-like cell cytokine production. Exp Ther Med. 2013; 5 (1): 165–169.

Dhaouadi T, Sfar I, Bardi R, Jendoubi-Ayed S, Abdallah TB, Ayed K et al. Cytokine gene polymorphisms in kidney transplantation. Transplant Proc. 2013; 45 (6): 2152–2157.

Javor J, Ferencik S, Bucova M, Stuchlikova M, Martinka E, Barak L et al. Polymorphisms in the genes encoding TGF-beta1, TNF-alpha, and IL-6 show association with type 1 diabetes mellitus in the Slovak population. Arch Immunol Ther Exp. 2010; 58 (5): 385–393.

Kim YH, Kim TH, Kang SW, Kim HJ, Park SJ, Jeong KH et al. Association between a TGFBR2 gene polymorphism (rs2228048, Asn389Asn) and acute rejection in Korean kidney transplantation recipients. Immunol Invest. 2013; 42 (4): 285–295.

Mu HJ, Xie P, Chen JY, Gao F, Zou J, Zhang J et al. As sociation of TNF-alpha, TGF-beta1, IL-10, IL-6 And IFN-gamma Gene Polymorphism with Acute Rejection and Infection in Lung Transplant Recipients. Clin Transplant. 2014; 26 (10): 12411.

Paladino N, Flores AC, Fainboim H, Schroder T, Cuarter olo M, Lezama C et al. The most severe forms of type I autoimmune hepatitis are associated with genetically determined levels of TGF-beta1. Clin Immunol. 2010; 134 (3): 305–312.

Nikolova PN, Ivanova MI, Mihailova SM, Myhailova AP, Ba ltadjieva DN, Simeonov PL et al. Cytokine gene polymorphism in kidney transplantation-impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl Immunol. 2008; 18 (4): 344–348.

Perez AB, Sierra B, Garcia G, Aguirre E, Babel N, Alvare z M et al. Tumor necrosis factor-alpha, transforming growth factor-beta1, and interleukin-10 gene olymorphisms:

implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol. 2010; 71 (11):1135–1140.

Eurich D, Neumann UP, Boas-Knoop S, Neuhaus R, Bahra M, Neuhaus P et al. Transforming growth factorbeta1-gene polymorphism in the development of kidney disease after liver transplantation. Transplantation. 2012; 93 (5): 555–560.

Eurich D, Bahra M, Boas-Knoop S, Lock JF, Golembus J, Neuh aus R et al. Transforming growth factor beta1 polymorphisms and progression of graft fi brosis after liver transplantation for hepatitis C virus-induced liver disease. Liver Transpl. 2011; 17 (3): 279–288.

Xie HY, Wang WL, Yao MY, Yu SF, Feng XN, Jin J et al. Polym orphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients. Arch Med Res. 2008; 39 (4): 420–428.

Kumar R, Goswami R, Agarwal S, Israni N, Singh SK, Rani R. A ssociation and interaction of the TNF-alpha gene with other pro- and anti-infl ammatory cytokine genes and HLA genes in patients with type 1 diabetes from North India. Tissue Antigens. 2007; 69 (6): 557–567.

The authors declare that there are no conflicts of interest present.